Cornea/External Disease News

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, John D. Sheppard, MD, MMSc, discusses the use of Vevye from Harrow to treat dry eye disease.

Lumenis announced the launch of OptiPlus, its new dual-frequency radiofrequency device that delivers heat across different tissue layers to increase blood circulation and target dry eye inflammation due to meibomian gland dysfunction.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Preeya K. Gupta, MD, discusses a clinical trial comparing the TearCare system with Restasis for the treatment of dry eye disease and meibomian gland dysfunction.

NEW ORLEANS — The CLEK study continues to inform keratoconus management today, from contact lens fitting to understanding patient quality of life, according to Susan J. Gromacki, OD, MS, FAAO, FSLS, at Academy ’23.

Epion Therapeutics has initiated its phase 3 Apricity trials for EpiSmart, a minimally invasive drug-device combination indicated for epithelium-on cross-linking in the treatment of keratoconus.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Penny A. Asbell, MD, FACS, MBA, presents data from the ARMOR study investigating antibiotic resistance patterns among endophthalmitis isolates.

SAN FRANCISCO — Although Descemet’s membrane endothelial keratoplasty is gaining popularity, Descemet’s stripping endothelial keratoplasty still has a place in challenging cases, according to an expert.

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Eris Jordan, OD, vice president of global clinical and medical affairs at Aurion Biotech, discusses the company’s novel cell therapy for corneal endothelial disease.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Brandon D. Ayres, MD, discusses data from the SAHARA trial, which evaluated patients with dry eye disease and meibomian gland dysfunction.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Edward J. Holland, MD, and Shigeru Kinoshita, MD, PhD, discuss the U.S. phase 1/2 trial for Aurion Bitoech’s AURN001 cell therapy for treatment of corneal edema.